On May 5, President Donald Trump issued an executive order prohibiting future federal funding for gain-of-function research. This decision highlights ongoing discussions about the shortcomings in the country’s pandemic response, which extend well beyond laboratory practices.
As the intense phase of the Covid-19 pandemic recedes, the US is reflecting on various aspects of its response—closures, vaccines, school disruptions, and public trust. However, there’s one critical lesson that remains unacknowledged: an effective health strategy during a crisis needs to be multifaceted. Relying on a binary approach to Covid-19 has costs, not just financially, but in health outcomes as well. The nation needs to improve its readiness for future crises.
Throughout the pandemic, the public often received a stark directive: get vaccinated or risk infection. While vaccination was essential for most, policymakers should have embraced a broader perspective. Medicine is rarely one-size-fits-all. The virus has changed, and patient responses have varied significantly, yet the official response remained rigid and unyielding.
What was required was a dynamic public health strategy that incorporates various tools—vaccines, antiviral medications, monoclonal antibodies, and advancements in biology.
A truly resilient health system can pivot and align treatments to patient needs while adapting as science advances.
Monoclonal antibodies are a prime illustration of a mismanaged response. Initially shown to reduce hospitalizations and deaths in high-risk patients, these treatments were widely used but their distribution halted by federal authorities between late 2021 and early 2022, citing diminished effectiveness against new variants. This was a significant error. Monoclonal antibodies are adaptable and could have been tailored to target emerging variants effectively, particularly for individuals who do not respond well to vaccines. Yet, even years into the pandemic, they haven’t fully received FDA approval for respiratory virus prevention, despite meeting safety and efficacy standards similar to other expedited medical treatments.
Meanwhile, the public was encouraged to rely primarily on booster shots, which, while somewhat beneficial, have lost their effectiveness. Data from the CDC indicate that the bivalent booster only offers 37% protection against hospitalization for seniors after several months, with even lower efficacy for those with weakened immune systems. Unfortunately, potential treatments that could have filled this gap were sidelined.
Trump’s decision to restrict research into “dangerous” gain-of-function studies is indeed prudent. The United States must sustain existing treatment strategies and empower healthcare professionals to tailor recommendations based on individual patient needs.
Looking ahead, five years after the pandemic began, the US still lacks a proactive, adaptive framework for deploying practical and evidence-based therapeutics in public health emergencies. What’s needed is a system that ensures a diverse range of tools, rather than relying solely on the initial market responses.
This requires investment in organizations such as the Bureau of Advanced Biomedical Research and Development and the National Institutes of Health, focusing on versatile solutions like antibody platforms, a wider range of antiviral agents, rapid diagnostics, and therapeutic RNA technologies. It also necessitates updating the FDA’s approval process to keep pace with innovations, allowing regulators to act swiftly when data indicates a treatment can save lives.
Congress can assist by creating funding models that reward adaptability, encouraging businesses to develop and maintain diverse treatment strategies, and ensuring public-private partnerships are quick and scalable. Establishing a permanent procurement mechanism for vaccines and variant-specific updates could enhance preparedness.
All these measures could help rebuild trust in American health institutions, which suffered dramatically during the pandemic due to perceptions of opaqueness and an inability to address the varied needs of patients.
A 2022 Pew Research Center survey showed only 29% of US adults expressed strong confidence in medical scientists, a decline from 40% early in the pandemic, with trust in public health officials following a similar trend.
A more open and inclusive approach is vital. Policymakers need to clearly communicate the rationale for changes in treatment strategies and transparently evaluate real-world results to regain public trust. Emphasizing data sharing, clear communication, and respecting physicians’ judgment in personalizing patient care is essential.
The Covid-19 pandemic has highlighted significant flaws in the current US health response strategy. A more effective approach moving forward will require adaptability, diversity in methods, and humility from health policymakers. If future regulation fosters innovation, real-time result evaluation, and keeps all safe and effective tools accessible, perhaps these lessons won’t have to be relearned in the future.
